Trials / Completed
CompletedNCT01369511
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2495655 | Administered subcutaneously |
| DRUG | Placebo | Administered subcutaneously |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2011-06-09
- Last updated
- 2018-06-06
- Results posted
- 2018-06-06
Locations
45 sites across 11 countries: United States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Japan, Spain, Sweden
Source: ClinicalTrials.gov record NCT01369511. Inclusion in this directory is not an endorsement.